Key result
Among patients with chronic heart failure and reduced ejection fraction, 68.3% were prescribed RAS modulators, but only 32.7% of these patients received an optimal dose.
Why the study?
Despite established benefits, evidence regarding real-world prescribing patterns, dose optimization, and factors influencing renin-angiotensin system modulator use in chronic heart failure with reduced ejection fraction remains limited.
Population
385 chronic heart failure patients with reduced ejection fraction at Northwest Ethiopian PCSHs
Comparison
Use and dose optimization vs non-use or suboptimal dosing of RAS modulators
Design
Hospital-based multicenter cohort study
Authors
Loading...
Suboptimal RAS modulator dosing in real-world HFrEF warrants closer monitoring; leaves open targeted strategies to close implementation gaps.
Cohort (n=385)
Yes
There is significant underutilization and suboptimal dosing of RAS modulators among patients with HFrEF in resource-limited settings, highlighting a major gap in the implementation of guideline-directed medical therapy.
Anberbr et al. (2025) conducted a cohort in chronic heart failure with reduced ejection fraction (n=385). Renin-angiotensin system (RAS) modulators was evaluated on Prescription of RAS modulators. Among patients with chronic heart failure and reduced ejection fraction, 68.3% were prescribed RAS modulators, but only 32.7% of these patients received an optimal dose.